Works Cited

1. Ackerman S. Discovering the Brain. Washington, DC: National Academies Press; 1992.

2. Science Daily. MR Technique Shows Brains of Alzheimer's Patients Similar to Immature Brains in Children. Available at https://www.sciencedaily.com/releases/2003/05/030507080247.htm. Last accessed March 15, 2021.

3. Alzheimer's Association. Public Policy Victories. Available at https://www.alz.org/get-involved-now/advocate/victories. Last accessed March 15, 2021.

4. U.S. Department of Health and Human Services. National Plan to Address Alzheimer's Disease: 2017 Update. Available at https://aspe.hhs.gov/report/national-plan-address-alzheimers-disease-2017-update. Last accessed March 15, 2021.

5. O'Brien M. Successful Aging. Concord, CA: Biomed General; 2005.

6. Murphey C. Aging is an Attitude: Positive Ways to Look at Getting Older. Chattanooga, TN: Living Ink Publishers; 2005.

7. Administration on Aging. 2019 Profile of Older Americans. Available at https://acl.gov/sites/default/files/Aging%20and%20Disability%20in%20America/2019ProfileOlderAmericans508.pdf. Last accessed March 15, 2021.

8. Fernandes MA, Pacurar A, Moscovitch M, Grady C. Neural correlates of auditory recognition under full and divided attention in younger and older adults. Neuropsychologia. 2006;44(12):2452-2464.

9. Alzheimer's Association. 2021 Alzheimer's Disease Facts and Figures. Available at https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf. Last accessed March 15, 2021.

10. Mosconi LG, Glodzik L, Mistur R, et al. Oxidative stress and amyloid-beta pathology in normal and individuals with a maternal history of Alzheimer's. Biol Psychiatry. 2010;68(10):913-921.

11. Bergland C. What Is the Best Way to Improve Your Brain Power For Life? Available at https://www.psychologytoday.com/us/blog/the-athletes-way/201401/what-is-the-best-way-improve-your-brain-power-life. Last accessed March 15, 2021.

12. Alzheimer's Association. Brain Health. Available at https://www.alz.org/help-support/brain_health. Last accessed March 15, 2021.

13. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab. 2012;32(3):425-436.

14. Willis SL, Tennstedt SL, Marsiske M et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA. 2006;296(23):2805-2814.

15. National Institute on Aging. Alzheimer's Disease Genetics Fact Sheet. Available at https://www.nia.nih.gov/health/alzheimers-disease-genetics-fact-sheet. Last accessed March 15, 2018.

16. Lewy Body Dementia Association. Healthcare Professionals: Treatment. Available at https://www.lbda.org/treatment. Last accessed March 18, 2021.

17. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic study on aging. Neurology. 2010;75(10):889-897.

18. Stagnitti MN. Person Characteristics of the Elderly Reporting One or More Cognitive Disorders, 2007. Available at https://meps.ahrq.gov/data_files/publications/st310/stat310.shtml. Last accessed March 16, 2021.

19. Smith JC, Nielson KA, Woodard JL, et al. Interactive effects of physical activity and APOE-ε4 on BOLD semantic memory activation in healthy elders. Neuroimage. 2011;54(1):635-644.

20. Martin RC, Annis SM, Darling LZ, Wadley V, Harrell L, Marson DC. Loss of calculation abilities in patients with mild and moderate Alzheimer disease. Arch Neurol. 2003;60(11):1585-1589.

21. Mayo Clinic. Dementia. Available at https://www.mayoclinic.org/diseases-conditions/dementia/symptoms-causes/syc-20352013. Last accessed March 16, 2021.

22. Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361(16):1529-1538.

23. Alzheimer's Association. Types of Dementia. Available at https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia. Last accessed March 16, 2021.

24. Green R. Diagnosis and Management of Alzheimer's Disease and Other Dementias. 2nd ed. West Islip, NY: Professional Communications; 2005.

25. National Task Group on Intellectual Disabilities and Dementia Practices. NTG-Early Detection and Screen for Dementia (NTG-EDSD). Available at https://www.the-ntg.org/ntg-edsd. Last accessed March 16, 2021.

26. Lewy Body Dementia Association. 10 Things You Should Know About LBD. Available at https://www.lbda.org/10-things-you-should-know-about-lbd. Last accessed March 16, 2021.

27. Alzheimer's Association. Lewy Body Dementia. Available at https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/lewy-body-dementia. Last accessed March 16, 2021.

28. Shankle W, Amen D. Preventing Alzheimer's: Ways to Help Prevent, Delay, Detect, and Even Halt Alzheimer's Disease and Other Forms of Memory Loss. New York, NY: Penguin Group; 2004.

29. Alzheimer's Association. 10 Early Signs and Symptoms of Alzheimer's. Available at https://www.alz.org/alzheimers-dementia/10_signs. Last accessed March 16, 2021.

30. National Institute on Aging. One in Seven Americans Age 71 and Older Has Some Type of Dementia, NIH-Funded Study Estimates. Available at https://www.nih.gov/news-events/news-releases/one-seven-americans-age-71-older-has-some-type-dementia-nih-funded-study-estimates. Last accessed March 21, 2021.

31. Fodale V, Ritchie K, Rasmussen LS, Mandal PK. Anesthetics and Alzheimer's disease: research and background. J Alzheimers Dis. 2010;22(S3):1-3.

32. Crystal HA. Dementia with Lewy Bodies. Available at https://emedicine.medscape.com/article/1135041-overview. Last accessed March 16, 2021.

33. Hamilton J. Considering alternative causes of dementia: is it Alzheimer's disease or dementia with Lewy bodies? California Psychol. 2010;43(6):12-14.

34. Suda S, Sugihara G, Suyama R, Mori N, Takei N. Donepezil and concurrent sertraline treatment is associated with increased hippocampal volume in a patient with depression. J Clin Psychiatry. 2010;71(6):806-808.

35. Snowdon DA. Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologist. 1997;37(2):150-156.

36. Tyas SL, Snowdon DA, Desrosiers MF, Riley KP, Markesbery MR. Early-life linguistic ability, late-life pathology and asymptomatic Alzheimer's disease: findings from the Nun Study. Alzheimers Dement. 2005;5(4 Suppl):P103-P104.

37. Wendling P. Drinking, smoking may raise early AD risk. Clinical Psychiatry News. 2008;(5).

38. Sabia S, Marmot M, Dufouil C, Singh-Manoux A. Smoking history and cognitive function in middle age from the Whitehall II study. Arch Intern Med. 2008;168(11):1165-1173.

39. Wallin, C., Sholts, S.B., Österlund, N. et al. Alzheimer's disease and cigarette smoke components: effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-β peptide aggregation. Sci Rep. 2017;7:14423.

40. Yaffe K, Vittinghoff E, Lindquist K, et al. Posttraumatic stress disorder and risk of dementia among U.S. veterans. Arch Gen Psychiatry. 2010;67(6):608-613.

41. Andel R, Crowe M, Hahn EA, et al. Work-related stress may increase the risk of vascular dementia. J Am Geriatr Soc. 2012;60(1):60-67.

42. Erickson KI, Kramer AF. Aerobic exercise effects on cognitive and neural plasticity in older adults. Br J Sports Med. 2009;43:22-24.

43. Lowry F. Walking Slows the Progression of Alzheimer's Disease. Available at https://www.medscape.com/viewarticle/733242. Last accessed March 18, 2021.

44. Knöchel C, Oertel-Knöchel V, O'Dwyer L, et al. Cognitive and behavioural effects of physical exercise in psychiatric patients.Prog Neurobiol. 2012;96(1):46-68.

45. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108(7):3017-3022.

46. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296-1300.

47. Williams JW, Plassman BL, Burke J, Holsinger T, Benjamin S. Preventing Alzheimer's Disease and Cognitive Decline. Evidence Report/Technology Assessment No. 193. Rockville, MD: Agency for Healthcare Research and Quality; 2010.

48. Neugroschl J. Diet, depression and diabetes could modify dementia risk. Focus Healthy Aging. 2010;13(11):7.

49. Kerwin DR, Gaussoin SA, Chlebowski RT, et al. Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: results from the Women's Health Initiative Memory Study. J Am Geriat Soc. 2011;59(1):107-112.

50. Humpel C, Ullrich C, Pirchl M. Chronic high cholesterol diet produces brain damage. Mol Cell Neurosci. 2010;45(4):408-417.

51. Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA, Morris MC. Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr. 2011;93(3):601-607.

52. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51(4):1256-1262.

53. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2007;70:1672-1677.

54. Alzheimer's Disease Education and Referral Center. 2003 Progress Report on Alzheimer's Disease: Research Advances at NIH. Rockville, MD: U.S. Department of Health and Human Services; 2003.

55. National Institute on Aging. 2009 Progress Report on Alzheimer's Disease: Translating New Knowledge. Washington, DC: National Institute on Aging; 2010.

56. Williams J. Recent breakthroughs in understanding the genetics of Alzheimer's disease. Int J Neuropsychopharmacol. 2000;3(suppl 1):559.

57. Hedberg AG. Forms for the Therapist. New York, NY: Elsevier; 2010.

58. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.Alzheimers Dement. 2011;7(3):263-269.

59. Eckerström C. Hippocampal Volumetry in Mild Cognitive Impairment. Available at https://gupea.ub.gu.se/bitstream/2077/22902/2/gupea_2077_22902_2.pdf. Last accessed March 20, 2021.

60. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis. 2010;21(4):1119-1128.

61. Quinn JF, Raman R, Thomas R, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer's disease: a randomized trial. JAMA. 2010;304(17):1903-1911.

62. Bunce D, Anstey KJ, Cherbuin N, et al. Cognitive deficits are associated with frontal and temporal lobe white matter lesions in middle-aged adults living in the community. PLoS One. 2010;5(10):e13567.

63. George S, Mufson EJ, Leurgans S, Shah RC, Ferrari C, deToledo-Morrell L. MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD. Neurobiol Aging. 2011;32(10):1756-1764.

64. Alzheimer's Society. Dementia Risk Factors and Prevention. Available at https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=102. Last accessed March 20, 2021.

65. Frisardi V, Solfrizzi V, Capurso C, et al. Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. J Alzheimers Dis. 2010;20(1):17-30.

66. Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues JF. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol. 2009;169(4):489-496.

67. Varner JA, Jensen KF, Horvath W, Isaacson RL. Chronic administration of aluminum-fluoride or sodium-fluoride to rats in drinking water: alterations in neuronal and cerebrovascular integrity. Brain Res. 1998;784(1-2):284-298.

68. Schrag M, Mueller C, Oyoyo U, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol. 2011;94(3):296-306.

69. Alzheimer's Association. Stages of Alzheimer's Disease. Available at https://www.alz.org/national/documents/topicsheet_stages.pdf. Last accessed March 20, 2021.

70. Tang-Wai DF, Knopman DS, Geda YE, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol. 2003;60(12):1777-1781.

71. Ready RE, Paulsen JS. Neuropsychological studies in geriatric psychiatry. Curr Opin Psychiatry. 2003;16(6):643-648.

72. Agency for Health Care Policy and Research. Recognition and Initial Assessment of Alzheimer's Disease and Related Dementias. Pub. No. 97-R123. Rockville, MD: U.S. Department of Health and Human Services; 1996.

73. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer's disease and normal aging for clinical trials. Arch Neurol. 2004;61(1):59-66.

74. Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol. 2010;23(3):185-198.

75. Mold M, Linhart C, Gómez-Ramírez J, et al. Aluminum and amyloid-β in familial Alzheimer's disease. J Alz Dis. 2020;73(4):1627-1635.

76. Bonte FJ, Harris TS, Roney CA, Hynan LS. Differential diagnosis between Alzheimer's and frontotemporal disease by the posterior cingulate sign. J Nucl Med. 2004;45(5):771-774.

77. Scarmeas N, Zarahn E, Anderson KE, et al. Cognitive reserve-mediated modulation of positron emission tomographic activations during memory tasks in Alzheimer disease. Arch Neurol. 2004;61(1):73-78.

78. Gauthier S, Emire M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8):707-714.

79. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14(1):e1-e26.

80. Okamura N, Yanai K. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. IDrugs. 2010;13(12):890-899.

81. Mitsis EM, Bender HA, Kostakoglu L, et al. A consecutive case series experience with [18F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener. 2014;9:10.

82. DeMarco B. Seventy Percent of Newly Diagnosed Alzheimer's Patients Do Not Receive Treatment within a Year of Diagnosis. Available at https://decisionresourcesgroup.com/news/122605-seventy-percent-of-newly-diagnosed-alzheimers-disease-patients-do-not-receive-treatment-within-a-year-of-diagnosis. Last accessed March 20, 2021.

83. Cruz VT, Pais J, Teixeira A, Nunes B. The initial symptoms of Alzheimer's disease: caregiver perception. Acta Med Port. 2004;17(6):435-444.

84. Solfrizzi V, Frisardi V, Seripa D, et al. Mediterranean diet in predementia and dementia syndromes. Curr Alzheimer Res. 2011;8(5):520-542.

85. Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011;83(12):1403-1412.

86. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J Int Med Res. 2006;34(4):339-347.

87. National Institute on Aging. How is Alzheimer's Disease Treated? Available at https://www.nia.nih.gov/health/how-alzheimers-disease-treated. Last accessed March 20, 2021.

88. Alzheimer's Association. Medications for Memory. Available at https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory. Last accessed March 20, 2021.

89. Beier MT. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Pharmacotherapy. 2007;27(3):399-411.

90. Ramsey-Klawsnik H. Elder-abuse offenders. Generations. 2000;24(2):17-22.

91. American Association of Suicidology. USA Suicide: 2019 Final Data. Available at https://suicidology.org/wp-content/uploads/2021/01/2019datapgsv2b.pdf. Last accessed March 20, 2021.

92. Deblinger L. Alcohol problems in the elderly. Patient Care. 2000;3(10):68.

93. National Council on Alcoholism and Drug Dependence, Inc. Seniors and Alcohol. Available https://www.ncadd.org/about-addiction/seniors. Last accessed March 20, 2021.

94. National Council on Alcoholism and Drug Dependence, Inc. An Invisible Epidemic: Alcoholism and Drug Dependence Among Older Adults. Available at https://ncadd.org/images/stories/PDF/factsheet-alcoholismanddrugdependenceamongolderadults.pdf. Last accessed March 20, 2021.

95. Aging.com. Alcohol Abuse Amongst the Elderly: A Complete Guide. Available at https://aging.com/alcohol-abuse-amongst-the-elderly-a-complete-guide. Last accessed March 18, 2021.

96. National Institutes of Health. News Release: NIH Award Expands Landmark Alzheimer's Biomarker Study, ADNI Adds Novel Methods for Recruitment, Testing Disease Risk. Available at https://www.nih.gov/news-events/news-releases/nih-award-expands-landmark-alzheimers-biomarker-study. Last accessed March 20, 2021.

97. Phillips ML. The Mind at Midlife. Available at http://www.apa.org/monitor/2011/04/mind-midlife.aspx. Last accessed March 15, 2021.

98. Mejldal A, Andersen K, Bilberg R, et al. The Alcohol Dependence Scale and DSM-5 alcohol use disorder: severity ratings correspond insufficiently in older patients. Int J Methods Psychiatr Res. 2020;29:e1811.

99. Population Reference Bureau. The U.S. Population Is Growing Older, and the Gender Gap in Life Expectancy Is Narrowing. Available at https://www.prb.org/the-u-s-population-is-growing-older-and-the-gender-gap-in-life-expectancy-is-narrowing. Last accessed March 20, 2021.

100. National Institute on Alcohol Abuse and Alcoholism. Understanding Alcohol Use Disorder. Available at https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-use-disorder. Last accessed March 20, 2021.

101. Alzheimer's Association. Driving and Dementia. Available at https://www.alz.org/national/documents/statements_driving.pdf. Last accessed March 20, 2021.

102. Quinn KJ, Shah NH. A dataset quantifying polypharmacy in the United States. Sci Data. 2017;4:170167.

103. National Institute on Aging. Caring for a Person with Alzheimer's Disease. Available at https://order.nia.nih.gov/sites/default/files/2019-03/Caring_for_a_person_with_AD_508_0.pdf. Last accessed October 14, 2021.

Evidence-Based Practice Recommendations Citations

1. Registered Nurses' Association of Ontario. Delirium, Dementia, and Depression in Older Adults: Assessment and Care. Toronto: Registered Nurses' Association of Ontario; 2016. Available at https://rnao.ca/sites/rnao-ca/files/bpg/RNAO_Delirium_Dementia_Depression_Older_Adults_Assessment_and_Care.pdf. Last accessed March 24, 2021.

2. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2013;54(3):476-490. Available at http://s3.amazonaws.com/rdcms-snmmi/files/production/public/FileDownloads/HPRA/Appropriate%20use%20criteria%20for%20amyloid%20PET.pdf. Last accessed March 24, 2021.

3. U.S. Preventive Services Task Force. Screening for suicide risk in adolescents, adults, and older adults in primary care: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(10):719-726. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/suicide-risk-in-adolescents-adults-and-older-adults-screening. Last accessed March 24, 2021.


Copyright © 2021 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.